Jose Serrano1, Maren R Laughlin2, Melena D Bellin3, Dhiraj Yadav4, Vernon M Chinchilli5, Dana K Andersen1. 1. From the Divisions of Digestive Diseases and Nutrition. 2. Diabetes, Endocrine and Metabolism, National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD. 3. Schulze Diabetes Institute, University of Minnesota Medical Center, Minneapolis, MN. 4. Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center. 5. Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA.
Abstract
ABSTRACT: Acute pancreatitis (AP), resulting from inflammation of the pancreas, accounts for more than 300,000 US hospital discharges per year. Although glucose intolerance has been known as a complication of severe AP, this effect was thought to be transient. Recently, cohort studies and meta-analysis of 24 published studies of 1100 patients who survived one or more episodes of AP revealed that 30% to 40% of patients developed diabetes or impaired glucose tolerance within 3 to 4 years of even a single episode of AP. The National Institute of Diabetes and Digestive and Kidney Diseases funded the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC) to undertake a prospective observational study of the occurrence of diabetes during an AP episode or subsequently, with emphasis on type 1 diabetes. Key factors for funding T1DAPC are the increasing incidence and prevalence of AP, its association with the development of type 1 diabetes and other forms of diabetes after AP, its complications, and associated health care cost. The T1DAPC structure, governance, and research objectives are described in this article. The DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) studies to be undertaken by the T1DAPC are described in other articles in this journal's issue.
ABSTRACT: Acute pancreatitis (AP), resulting from inflammation of the pancreas, accounts for more than 300,000 US hospital discharges per year. Although glucose intolerance has been known as a complication of severe AP, this effect was thought to be transient. Recently, cohort studies and meta-analysis of 24 published studies of 1100 patients who survived one or more episodes of AP revealed that 30% to 40% of patients developed diabetes or impaired glucose tolerance within 3 to 4 years of even a single episode of AP. The National Institute of Diabetes and Digestive and Kidney Diseases funded the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC) to undertake a prospective observational study of the occurrence of diabetes during an AP episode or subsequently, with emphasis on type 1 diabetes. Key factors for funding T1DAPC are the increasing incidence and prevalence of AP, its association with the development of type 1 diabetes and other forms of diabetes after AP, its complications, and associated health care cost. The T1DAPC structure, governance, and research objectives are described in this article. The DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) studies to be undertaken by the T1DAPC are described in other articles in this journal's issue.
Authors: Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari Journal: Lancet Gastroenterol Hepatol Date: 2016-10-12
Authors: Anne F Peery; Seth D Crockett; Caitlin C Murphy; Jennifer L Lund; Evan S Dellon; J Lucas Williams; Elizabeth T Jensen; Nicholas J Shaheen; Alfred S Barritt; Sarah R Lieber; Bharati Kochar; Edward L Barnes; Y Claire Fan; Virginia Pate; Joseph Galanko; Todd H Baron; Robert S Sandler Journal: Gastroenterology Date: 2018-10-10 Impact factor: 22.682
Authors: Chris Woodmansey; Andrew P McGovern; Katherine A McCullough; Martin B Whyte; Neil M Munro; Ana C Correa; Piers A C Gatenby; Simon A Jones; Simon de Lusignan Journal: Diabetes Care Date: 2017-08-31 Impact factor: 19.112
Authors: G Angelini; G Cavallini; P Pederzoli; P Bovo; C Bassi; V Di Francesco; L Frulloni; D Sgarbi; G Talamini; A Castagnini Journal: Digestion Date: 1993 Impact factor: 3.216
Authors: Usama Ahmed Ali; Yama Issa; Julia C Hagenaars; Olaf J Bakker; Harry van Goor; Vincent B Nieuwenhuijs; Thomas L Bollen; Bert van Ramshorst; Ben J Witteman; Menno A Brink; Alexander F Schaapherder; Cornelis H Dejong; B W Marcel Spanier; Joos Heisterkamp; Erwin van der Harst; Casper H van Eijck; Marc G Besselink; Hein G Gooszen; Hjalmar C van Santvoort; Marja A Boermeester Journal: Clin Gastroenterol Hepatol Date: 2016-01-06 Impact factor: 11.382
Authors: Peter J Fagenholz; Carlos Fernández-del Castillo; N Stuart Harris; Andrea J Pelletier; Carlos A Camargo Journal: Pancreas Date: 2007-11 Impact factor: 3.327
Authors: Stephanie L M Das; Primal P Singh; Anthony R J Phillips; Rinki Murphy; John A Windsor; Maxim S Petrov Journal: Gut Date: 2013-08-08 Impact factor: 23.059
Authors: Phil A Hart; Georgios I Papachristou; Walter G Park; Anne-Marie Dyer; Vernon M Chinchilli; Elham Afghani; Venkata S Akshintala; Dana K Andersen; James L Buxbaum; Darwin L Conwell; Kathleen M Dungan; Jeffrey J Easler; Evan L Fogel; Carla J Greenbaum; Rita R Kalyani; Murray Korc; Richard Kozarek; Maren R Laughlin; Peter J Lee; Jennifer L Maranki; Stephen J Pandol; Anna Evans Phillips; Jose Serrano; Vikesh K Singh; Cate Speake; Temel Tirkes; Frederico G S Toledo; Guru Trikudanathan; Santhi Swaroop Vege; Ming Wang; Cemal Yazici; Atif Zaheer; Christopher E Forsmark; Melena D Bellin; Dhiraj Yadav Journal: Pancreas Date: 2022-07-01 Impact factor: 3.243
Authors: Anne-Marie Dyer; Kendall Thomas Baab; Aimee Merchlinski; Paula A Valencia-Moulton; Beth R Holmes; Ariana Pichardo-Lowden; Jose Serrano; Maren R Laughlin; Vernon M Chinchilli Journal: Pancreas Date: 2022-07-01 Impact factor: 3.243